)

TFF Pharmaceuticals (TFFP) investor relations material
TFF Pharmaceuticals Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
TFF Pharmaceuticals focuses on inhaled dry powder drugs using Thin Film Freezing (TFF) technology, with TFF TAC and TFF VORI as main candidates in Phase 2 trials as of June 2024.
Positive Phase 2 TFF TAC data show strong safety, efficacy, and biomarker improvements for lung transplant rejection prevention, with 13 patients enrolled and all completing 12 weeks opting for long-term extension.
No mortality or severe adverse events in TFF TAC trial; kidney function maintained and one minimal acute rejection case resolved.
The company prioritized TFF TAC development in March 2024 and is evaluating strategic options for TFF VORI.
Strategic initiatives include partnership evaluations, government-funded MCM development, and advancing universal influenza vaccines to preclinical testing.
Financial highlights
Revenue for Q2 2024 was $650,222, up 95% from $333,351 in Q2 2023, mainly from grants and feasibility agreements.
Net loss for Q2 2024 was $4.5 million, improved from $5.0 million in Q2 2023; net loss for the six months ended June 30, 2024 was $10.2 million, down from $12.1 million in the prior year period.
Operating expenses for Q2 2024 decreased 14% year-over-year to $4.6 million, with R&D at $2.6 million (down 3%) and G&A at $2.0 million (down 24%).
Cash and cash equivalents as of June 30, 2024 were $4.4 million, with working capital of $2.3 million.
Accumulated deficit reached $128.5 million as of June 30, 2024.
Outlook and guidance
Management expresses substantial doubt about the company’s ability to continue as a going concern over the next 12 months without additional capital.
The company plans to seek further funding through equity, debt, licensing, or partnerships and may adjust its business plan to conserve capital.
Enrollment in the TFF TAC Phase 2 study is expected to end in the second half of 2024; TFF VORI Phase 2 trials have concluded.
Next TFF TAC study design is being finalized with regulatory update expected later in the fall.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage